Gong, Z. et al. (2015) International Journal of Cancer
Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women’s Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use.
Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p<0.001), and of several site-specific cancers (HR, 1.2-1.4, and up to over 2-fold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p<0.001). There was no overall difference in cancer incidence by diabetes therapy (p=0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 versus 1.45; p=0.007) and for breast cancer (HRs, 0.50 versus 1.29; p=0.05).
Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long-term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti-diabetes medications. Future studies are needed to determine the long-term effect of metformin in cancer risk and survival from cancer.
A report from a national bowel cancer charity sets out five ambitions for the future of bowel cancer care.
These are: one million more people screened, no one with symptoms turned away, the best treatment for every patient, more bowel cancer nurses, and support for everyone after treatment.
Press release available here
NHS England has launched a 12-week consultation on draft proposals outlining a new Cancer Drugs Fund (CDF). The aim of the new CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the NHS in the future. The consultation period runs until 11 February 2016.
Additional link: NICE press release
Article first published online: 13 NOV 2015
National guidelines recommend that patients with a cancer diagnosis engage in regular physical activity to reduce cancer-related fatigue, maintain quality of life and physical function, and improve overall prognosis and survival. This study investigates oncology provider communications about physical activity during routine clinic visits with patients with early-stage breast, colon, or prostate cancer.
This study used a retrospective chart review for documentation of inquiries or recommendations pertaining to physical activity in clinician notes and after-visit patient summaries.
In a 1-month period, 55 oncology providers had 361 encounters (clinic visits) with early-stage cancer patients. Thirty-five percent of these encounters included a provider communication about “physical activity,” “exercise,” or “activity.” Encounters with a medical oncologist resulted in a physical activity communication 55% of the time, whereas encounters with other clinician specialties did so 20% of the time (P < .0001). The likelihood of a physical activity communication increased with patient age (P < .001). When the encounter was with a patient who was being seen for surveillance, chemotherapy, or endocrine treatment, the rate of physical activity communications was significantly higher (46%, 37%, and 58%, respectively) than the rate when the visit was during radiation treatment or surgery (6% and 19%, respectively; P < .0001).
This study shows that it is feasible for oncology providers to have physical activity communications during routine clinic visits; however, the frequency of physical activity communications varies among providers. Interventions are needed to remind and encourage all oncology providers to encourage their patients with early-stage cancer to be physically active.
via Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer – Nyrop – 2015 – Cancer – Wiley Online Library.
Cancer Nursing Practice. 14, 9, 27-33.
The National Confidential Enquiry into Patient Outcome and Death highlighted the need to improve patient outcomes and safety when undergoing chemotherapy. The audit discussed in this article assessed proactive telephone follow up by staff on a chemotherapy helpline after a patient’s first cycle of chemotherapy.
A list of patients eligible for proactive follow up was compiled from a database of those undergoing treatment. A subset of eligible patients consented to participate in a telephone satisfaction survey and 150 were eligible for proactive follow up. Of 131 calls made, most (90%) were successful and 61% reported a number of problems (range=0-5), the most common being gastrointestinal side effects and fatigue. Active management was required in 18% of patients.
Patients reported high levels of satisfaction with proactive follow up. Of those surveyed (n=49), all reported that the call was useful. The majority (98%) were satisfied with telephone calls as a means of follow up. Proactive telephone follow up is shown to be an effective and acceptable method that enhances quality of care.
via Patient satisfaction with telephone follow up after treatment : Cancer Nursing Practice: Vol. 14, No. 9 (RCNi)
Cancer Nursing Practice. 14, 9, 34-39
The aim of this review was to synthesise and critique the evidence on patients experiencing chemotherapy-induced nausea and vomiting (CINV) and how it affects quality of life (QoL).
CINV has been recognised internationally as a life-limiting side effect. The needs of patients are recognised but poorly managed, which has an adverse effect on their QoL. Patients are potentially vulnerable and may require ongoing nursing advocacy and support.
Databases were searched during September 2014, after which limitations and inclusion criteria were applied. Outcomes were clustered into four main themes: effect of acute and delayed nausea and vomiting on QoL; effect of highly emetogenic chemotherapy in comparison with moderately emetogenic chemotherapy; effect of non-pharmacological approaches in reducing the effects of CINV; and psychosocial effects of CINV on QoL.
The review exposed inconsistencies in symptom management during chemotherapy. CINV is prevalent despite use of antiemetic treatments. Further qualitative research is recommended to understand the effect CINV has on QoL and non-pharmacological approaches are presented to be considered as additions to care.
Read More: http://journals.rcni.com/doi/abs/10.7748/cnp.14.9.34.s21?af=R
via Effect of chemotherapy-induced nausea on patients’ quality of life : Cancer Nursing Practice: Vol. 14, No. 9 (RCNi).